Anaptysbio (ANAB) Total Liabilities (2016 - 2026)
Anaptysbio's (ANAB) quarterly Total Liabilities came in at $329.7 million in Q1 2026, down 21.89% YoY from $422.1 million in Q1 2025, and down 9.53% on a QoQ basis from $364.4 million in Q4 2025.
Anaptysbio (ANAB) Total Liabilities (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Total Liabilities data on file, last reported at $329.7 million in Q1 2026.
- Quarterly Total Liabilities fell 21.89% year-over-year to $329.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $329.7 million (down 21.89% YoY) and the FY2025 annual result came in at $364.4 million, down 24.69% from the prior year.
- Total Liabilities eased to $329.7 million in Q1 2026, from $364.4 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $625.2 million in Q1 2022 to a low of $329.7 million in Q1 2026.
- A 5-year average of $475.4 million and a median of $483.8 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 57.7% — and 2025, when it dropped 28.44%.
- Tracing ANAB's Total Liabilities over 5 years: stood at $610.4 million in 2022, then fell by 25.88% to $452.4 million in 2023, then grew by 6.95% to $483.8 million in 2024, then retreated by 24.69% to $364.4 million in 2025, then retreated by 9.53% to $329.7 million in 2026.
- The last three Total Liabilities figures came in at $329.7 million (Q1 2026), $364.4 million (Q4 2025), and $353.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 329.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.68 Mn |
| Dec 31, 2025 | 364.40 Mn |
| Sep 30, 2025 | 353.10 Mn |
| Jun 30, 2025 | 335.25 Mn |
| Mar 31, 2025 | 422.05 Mn |
| Dec 31, 2024 | 483.83 Mn |
| Sep 30, 2024 | 493.42 Mn |
| Jun 30, 2024 | 427.38 Mn |
| Mar 31, 2024 | 405.84 Mn |
| Dec 31, 2023 | 452.39 Mn |
| Sep 30, 2023 | 487.33 Mn |
| Jun 30, 2023 | 517.10 Mn |
| Mar 31, 2023 | 551.79 Mn |
| Dec 31, 2022 | 610.38 Mn |
| Sep 30, 2022 | 618.50 Mn |
| Jun 30, 2022 | 603.85 Mn |
| Mar 31, 2022 | 625.17 Mn |
| Dec 31, 2021 | 643.07 Mn |
| Sep 30, 2021 | 424.34 Mn |
| Jun 30, 2021 | 426.57 Mn |